Community Bank & Trust Waco Texas Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Community Bank & Trust Waco Texas cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,191 shares of the company’s stock after selling 601 shares during the period. Johnson & Johnson makes up 2.0% of Community Bank & Trust Waco Texas’ investment portfolio, making the stock its 13th biggest holding. Community Bank & Trust Waco Texas’ holdings in Johnson & Johnson were worth $8,782,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $765,000. Empowered Funds LLC increased its stake in Johnson & Johnson by 46.7% in the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after purchasing an additional 32,244 shares in the last quarter. Concurrent Investment Advisors LLC increased its stake in Johnson & Johnson by 0.8% in the 1st quarter. Concurrent Investment Advisors LLC now owns 72,368 shares of the company’s stock valued at $11,448,000 after purchasing an additional 608 shares in the last quarter. Bey Douglas LLC increased its stake in Johnson & Johnson by 4.6% in the 1st quarter. Bey Douglas LLC now owns 1,826 shares of the company’s stock valued at $289,000 after purchasing an additional 81 shares in the last quarter. Finally, Nixon Peabody Trust Co. increased its stake in Johnson & Johnson by 4.6% in the 1st quarter. Nixon Peabody Trust Co. now owns 111,636 shares of the company’s stock valued at $17,660,000 after purchasing an additional 4,942 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 1.5 %

NYSE:JNJ opened at $152.64 on Wednesday. The company has a market capitalization of $367.50 billion, a price-to-earnings ratio of 22.09, a price-to-earnings-growth ratio of 2.75 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a 50-day simple moving average of $162.10 and a 200 day simple moving average of $156.01. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.66 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on JNJ shares. TD Cowen dropped their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Sanford C. Bernstein increased their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $175.00.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.